Developing a new treatment for glioblastoma using a natural compound
Design, Synthesis, and Evaluation of ant-Glioblastoma Agents
This study is working on a new treatment for glioblastoma, a tough type of brain cancer, using a natural substance called neaumycin B, with the goal of making it safer and more effective by focusing on cancer cells while protecting healthy ones.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10647664 on NIH RePORTER |
What this research studies
This research focuses on creating a new therapy for glioblastoma, a highly aggressive brain cancer, using a natural product called neaumycin B. The project aims to synthesize this compound in larger quantities and develop analogs that are more stable and accessible for treatment. By targeting glioblastoma cells specifically, the research seeks to minimize toxicity to healthy cells, which could lead to more effective and safer treatment options. The study will also explore new biological targets to enhance the screening of additional compounds that may have anti-glioblastoma activity.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who have limited treatment options.
Not a fit: Patients with other types of cancer or those who do not have glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel and effective treatment option for patients with glioblastoma.
How similar studies have performed: Previous research has shown promise in developing targeted therapies for glioblastoma, but this approach using neaumycin B is relatively novel.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Floreancig, Paul E — University of Pittsburgh at Pittsburgh
- Study coordinator: Floreancig, Paul E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.